Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-finding study of TS-172 in hyperphosphatemia patients on hemodialysis
jRCT2031220587Phase 2Completed
- Sponsor
- Taisho Pharmaceutical
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TS-172 in hyperphosphatemia, chronic kidney disease (CKD), sponsored by Taisho Pharmaceutical. Started Feb 2023; status: completed.
02
Drugs
TS-172
03
Conditions
hyperphosphatemiachronic kidney disease (CKD)
Beyond the preview
Go deeper on jRCT2031220587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220587.